September 17, 2014
WASHINGTON (AP) - The Food and Drug Administration says it has approved a new form of a best-selling breast cancer drug that targets tumor cells while sparing healthy ones.
The drug Kadcyla (kad-SY'-luh) from Roche combines the established drug Herceptin with a powerful chemotherapy and a third chemical linking the medicines together. The chemical keeps the drugs intact until they bind to a cancer cell, where the double-shot of medication is released.
The FDA approved the drug for about 20 percent of breast cancer patients who have a particular form of the disease. These patients have tumors that overproduce the protein HER-2.
The approval will help Roche build on the success of Herceptin, which has long dominated the breast cancer marketplace. The drug had sales of $6 billion last year.
Copyright 2014 Associated Press. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Viewers with disabilities can get assistance accessing this station's FCC Public Inspection File by contacting the station with the information listed below. Questions or concerns relating to the accessibility of the FCC's online public file system should be directed to the FCC at 888-225-5322, 888-835-5322 (TTY), or firstname.lastname@example.org.